Healthcare Industry News:  MicroThermX 

Devices Interventional Distribution

 News Release - May 5, 2011

BSD Medical Signs Agreement with CoMedical, Inc. for Distribution of MicroThermX(R) Microwave Ablation Products

SALT LAKE CITY--(Healthcare Sales & Marketing Network)-- BSD Medical Corporation (NASDAQ:BSDM ) (Company or BSD) (, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has signed an agreement with CoMedical, Inc. for the sales and distribution of the MicroThermX® Microwave Ablation (MicroThermX®) line of products. CoMedical is an established leading seller of minimally invasive surgical products, specializing in the marketing of innovative products to the interventional radiology market. CoMedical has a 31-year history of selling state-of-the-art medical devices and has been involved in the market launch of numerous leading-edge devices to the interventional radiology field. The agreement provides CoMedical rights to market the MicroThermX® line of products in the states of Washington, Oregon, Montana, Idaho, and Alaska. CoMedical has a team of veteran sales personnel covering this geographic area.

As part of its strategic initiative to capitalize on the large ablation market, BSD is nearing its goal of establishing a US, exclusive, specialty distribution network that provides nationwide sales coverage for the MicroThermX® line of products. Distributors have been selected on the basis of their current synergistic product sales mix and focus in the field of interventional oncology/radiology. BSD has trained the majority of the sales representatives who will be selling the MicroThermX® line of products in the US. To support this strategic initiative, BSD continues to expand its sales management team, who will work hand-in-hand with the sales representatives, assisting in the selling process and providing ongoing training and clinical support.

About the MicroThermX® Microwave Ablation System

The MicroThermX® Microwave Ablation System is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System, which allows BSD to market the MicroThermX® system in Europe. CE marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX® to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Source: BSD Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.